227 Detecting early markers of CF-related pulmonary exacerbations using home telemetry and sputum biomarkers

Ukor, E.F.; Ryan, Jamie; Brown, Karen; Haworth, C.S.; Auton, Kevin; Floto, Andres

doi:10.1016/s1569-1993(14)60362-3

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a clinical trial sponsored by Papworth Hospital during 2013, data were collected by 15 CF participants and uploaded electronically to Activ8rlives, a Web-based data collection and viewing system developed by Aseptika. The study indicated that clinical parameters and sputum biomarker changes are likely to enable early detection of exacerbations in CF patients and have a role in highlighting treatment failure [ 7 ]. The Self-Management Checks to Predict Exacerbations of Pseudomonas Aeruginosa in Patients with Long-Term Respiratory Conditions (SENSOR) study aims to investigate if these tools can be more widely applied to other respiratory conditions such as COPD and non-CF bronchiectasis (NCFB).…”

Section: Introductionmentioning

confidence: 99%

The SENSOR Study: Protocol for a Mixed-Methods Study of Self-Management Checks to Predict Exacerbations of Pseudomonas Aeruginosa in Patients with Long-Term Respiratory Conditions

Roberts¹,

Jones²,

Gunatilake³

et al. 2017

JMIR Res Protoc

View full text Add to dashboard Cite

BackgroundThere are an estimated three million people in the United Kingdom with chronic obstructive pulmonary disease (COPD), and the incidence of bronchiectasis is estimated at around 0.1% but is more common in COPD and severe asthma. Both COPD and bronchiectasis are characterized by exacerbations in which bacteria play a central role. Pseudomonas aeruginosa is isolated from sputum samples from 4% to 15% of adults with COPD and is more likely to be isolated from patients with severe disease. Earlier detection of exacerbations may improve morbidity and mortality by expediting treatment. Aseptika Ltd has developed a system for patients to self-monitor important physiological measurements including levels of physical activity, peak flow, forced expiratory volume (FEV1), and biomarkers for P aeruginosa in sputum.ObjectiveWe aim to test this system in 20 participants with P aeruginosa colonization and 10 controls with Haemophilus influenzae.MethodsWe plan to recruit 30 adult participants with COPD or non-CF bronchiectasis who have cultured P aeruginosa or H influenzae during an exacerbation in the last 6 months. They must produce sputum on most days and should have been stable for 4 weeks prior to entry. Daily data collected will include symptoms, health care usage, medication, weight, FEV1, physical activity level, blood pressure, oxygen saturation, and temperature. Sputum and urine samples will be provided daily. These data will be analyzed to assess predictive value in detecting upcoming exacerbations. Qualitative data will be gathered through self-administered questionnaires and semistructured interviews to gather information on participant coping and their use of the technology involved.ResultsRecruitment has been completed and results from the study should be available at the end of 2017.ConclusionsThe SENSOR study aims to test a home-monitoring system in people with chronic airway infection and is currently underway.

show abstract

Section: Introductionmentioning

confidence: 99%